Kavita Pal, MD
Pulmonary Disease · Atlanta, GANPI 1205194347
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,897 of the $5,780 with a category attached, or 67.4%. 32 manufacturers reported payments, led by Intuitive Surgical at 33.6% of the total. 2025 is the largest year on record at $3,376, more than ten times the $140 reported in 2019.
Across 157 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$2K
- AstraZeneca$919
- GSK$787
- Inari Medical, Inc.$297
- Boehringer Ingelheim$257
- Regeneron Healthcare Solutions, Inc.$197
- plus $1K from 26 others
What the payments were for
- Travel & lodging$3837%
- Food & beverage$3,89767%
- Education$1,50026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 11 | $1,943 |
| AstraZeneca | 20 | $919 |
| GSK | 46 | $787 |
| Inari Medical, Inc. | 4 | $297 |
| Boehringer Ingelheim | 8 | $257 |
| Regeneron Healthcare Solutions, Inc. | 8 | $197 |
| Actelion Pharmaceuticals US, Inc. | 6 | $143 |
| Verona Pharma, Inc. | 4 | $128 |
| Amgen | 6 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $111 |
| Grifols USA, LLC | 4 | $95 |
| United Therapeutics Corporation | 3 | $76 |
| Bayer | 3 | $71 |
| Insmed, Inc. | 2 | $63 |
| Mylan Specialty L.p. | 3 | $59 |
| AbbVie | 2 | $58 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| Merck | 2 | $43 |
| Sanofi | 1 | $37 |
| Baxter Healthcare | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Johnson & Johnson | 1 | $34 |
| Inogen, Inc. | 2 | $32 |
| Grifols Shared Services North America, Inc. | 1 | $32 |
| Electromed, Inc. | 2 | $27 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Boston Scientific | 1 | $23 |
| Phadia US Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $19 |
| Shionogi Inc | 1 | $15 |
| Novartis | 1 | $14 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$1,845
- FASENRA$373
- FLOWTRIEVER CATHETER, S$177
- CT THROMBECTOMY SYSTEM KIT$177
- TEZSPIRE$132
How this compares
$5,780 in reported general payments places this provider in the 60th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 66 | $57,572 |
| Breo ElliptaFluticasone/Vilanterol | 71 | $32,298 |
| EliquisApixaban | 30 | $24,303 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $21,871 |
| Spiriva RespimatTiotropium Bromide | 13 | $10,629 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $6,962 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $5,517 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,717 |
| Arnuity ElliptaFluticasone Furoate | 14 | $3,276 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $2,708 |
| Wixela InhubFluticasone Propion/Salmeterol | 12 | $1,391 |
| Ventolin HfaAlbuterol Sulfate | 20 | $1,114 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $710 |
| Ipratropium Bromide | 17 | $541 |
| Azithromycin | 37 | $518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $787 | $115,017190 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $919 | $11,67925 claims |
| Boehringer IngelheimSpiriva Respimat | $257 | $10,62913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Atlanta
- Colin SwensonAtlanta$255K
- Eric FlenaughAtlanta$93K
- Gregory MartinAtlanta$88K
- Victor TsengAtlanta$55K
- Ralitza MartinAtlanta$48K
- Venkatesh LakshminarayananAtlanta$33K
- Sisir AkkineniAtlanta$21K
- Gerald StatonAtlanta$21K
- Mirza AliAtlanta$16K
- Srihari VeeraraghavanAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.